Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2009-06-08 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MONTANAY (69250), Rhone
PHARMACIE DE MONTANAY : revenue, balance sheet and financial ratios
PHARMACIE DE MONTANAY is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MONTANAY (69250),
this company of category PME
shows in 2024 a revenue of 1.7 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DE MONTANAY (SIREN 513125898)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
1 738 203 €
1 699 881 €
1 702 291 €
1 550 521 €
1 381 457 €
1 213 223 €
1 159 544 €
1 159 240 €
Net income
51 655 €
70 659 €
49 315 €
64 998 €
83 541 €
74 104 €
80 427 €
74 750 €
65 913 €
EBITDA
N/C
91 162 €
61 898 €
84 280 €
115 305 €
101 960 €
46 891 €
37 365 €
34 564 €
Net margin
N/C
4.1%
2.9%
3.8%
5.4%
5.4%
6.6%
6.4%
5.7%
Revenue and income statement
In 2025, PHARMACIE DE MONTANAY generates positive net income of 52 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 66 k€ -> 52 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
51 655 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 94%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
94.111%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
43.051%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DE MONTANAY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
76.893
55.461
39.664
26.447
29.346
161.517
147.719
115.38
94.111
Financial autonomy
50.582
56.809
63.054
68.297
30.514
32.401
31.565
37.416
43.051
Repayment capacity
6.399
4.721
3.499
2.781
1.283
10.744
12.056
7.727
None
Cash flow / Revenue
5.942%
6.564%
6.805%
5.523%
5.472%
3.847%
2.992%
4.163%
None%
Sector positioning
Debt ratio
94.112025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average-6 pts over 3 years
In 2025, the debt ratio of PHARMACIE DE MONTANAY (94.11) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
43.05%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average+8 pts over 3 years
In 2025, the financial autonomy of PHARMACIE DE MONTANAY (43.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
7.73 years2024
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Average
In 2024, the repayment capacity of PHARMACIE DE MONTANAY (7.73) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 152.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
152.335
Liquidity indicators evolution PHARMACIE DE MONTANAY
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
181.057
166.754
172.625
159.014
41.38
208.067
138.224
152.301
152.335
Interest coverage
20.863
15.185
8.756
2.458
0.758
1.514
1.885
1.159
None
Sector positioning
Liquidity ratio
152.342025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average+9 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE DE MONTANAY (152.34) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
1.16x2024
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Average
In 2024, the interest coverage of PHARMACIE DE MONTANAY (1.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DE MONTANAY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
146 227 €
158 753 €
152 247 €
151 297 €
-372 156 €
141 665 €
94 564 €
164 747 €
0 €
Inventory turnover (days)
38
36
37
36
31
30
34
35
0
Customer payment term (days)
10
12
9
8
10
7
11
12
0
Supplier payment term (days)
34
43
40
39
49
37
39
47
0
Positioning of PHARMACIE DE MONTANAY in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DE MONTANAY is estimated at
820 545 €
(range 556 826€ - 1 287 549€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
556k€820k€1287k€
820 545 €Range: 556 826€ - 1 287 549€
NAF 5 année 2025
Valuation method used
Net Income Multiple
51 655 €
×
15.9x
=820 546 €
Range: 556 826€ - 1 287 549€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DE MONTANAY with other companies in the same sector:
Frequently asked questions about PHARMACIE DE MONTANAY
What is the revenue of PHARMACIE DE MONTANAY ?
The revenue of PHARMACIE DE MONTANAY in 2024 is 1.7 M€.
Is PHARMACIE DE MONTANAY profitable?
Yes, PHARMACIE DE MONTANAY generated a net profit of 52 k€ in 2025.
Where is the headquarters of PHARMACIE DE MONTANAY ?
The headquarters of PHARMACIE DE MONTANAY is located in MONTANAY (69250), in the department Rhone.
Where to find the tax return of PHARMACIE DE MONTANAY ?
The tax return of PHARMACIE DE MONTANAY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DE MONTANAY operate?
PHARMACIE DE MONTANAY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart